Genetic screening of compounds used in drug abuse treatment. II. Methadone.
Several compounds used clinically in drug abuse therapy were evaluated for genetic activity in a series of in vivo and in vitro assays. The second report in this series describes the results for one of these compounds, Methadone. A previous report described the results for Naltrexone. Methadone is a synthetic narcotic analgesic used as a substitute for Heroin in drug detoxification programs. Methadone demonstrated weak activity in the E. coli DNa repair system and in the Neurospora crassa and the mouse lymphoma forward-mutation assays under the conditions of this evaluation. Additional analysis of the ad-3 mutants induced by a related compound, LAAM, in Neurospora indicated that they were the result of a parasexual phenomena rather than forward mutation. Therefore, the methadone-induced ad-3 mutants also may be due to a parasexual phenomena.
D000818:Animals; D001854:Bone Marrow Cells; D002478:Cells, Cultured; D004260:DNA Repair / Q000187:drug effects; D004353:Drug Evaluation, Preclinical; D005796:Genes / Q000187:drug effects; D006801:Humans; D008223:Lymphoma / Q000235:genetics; D008691:Methadone / Q000633:toxicity*; D051379:Mice; D009153:Mutagens; D009374:Neoplasms, Experimental / Q000235:genetics; D009492:Neurospora crassa / Q000187:drug effects; D019966:Substance-Related Disorders / Q000188:drug therapy
D009153:Mutagens; D008691:Methadone